.

Browsing Gilbert and Rose-Marie Chagoury School of Medicine by Author "El-Amm, Joelle"

LAUR Repository

Browsing Gilbert and Rose-Marie Chagoury School of Medicine by Author "El-Amm, Joelle"

Sort by: Order: Results:

  • Bone-targeted therapies in metastatic castration-resistant prostate cancer 
    El-Amm, Joelle; Freeman, Ashley; Patel, Nihar; Aragon-Ching, Jeanny B. (2017-09-22)
    Majority of patients with metastatic castrate resistant prostate cancer (mCRPC) develop bone metastases which results in significant morbidity and mortality as a result of skeletal-related events (SREs). Several bone-targeted ...
  • Complications of allogeneic hematopoietic stem cell transplantation 
    El-Amm, Joelle; Arnaout, Karim; Patel, Nihar; Jain, Maneesh; Amro, Farah; Tabbara, Imad A. (2017-09-22)
    Infection, graft-versus-host disease (GVHD), and to a lesser extent sinusoidal obstructive syndrome (SOS) represent the major causes of morbidity and mortality in patients undergoing allogeneic hematopoietic stem cell ...
  • Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer 
    El-Amm, Joelle; Nassabein, Rami; Aragon-Ching, Jeanny B. (2017-09-25)
    Abiraterone acetate has established a major role in the treatment paradigm of metastatic castration-resistant prostate cancer ever since pivotal trials, COU-AA-301 and COU-AA-302, have shown benefit in both the second-line ...
  • The infrequent removal of retrievable IVC filters 
    El-Amm, Joelle; Mobarek, Dalia A.; Furmark, Lena; Aggarwal, Lena; Faselis, Charles; Rickles, Frederick R. (2017-09-25)
    On August 9, 2010, the US Food and Drug Administration (FDA) issued a safety communication warning that retrievable Inferior Vena Cava (IVC) filters, which are intended for short-term placement are not always removed once ...
  • Metastatic castration-resistant prostate cancer 
    El-Amm, Joelle; Patel, Nihar; Freeman, Ashley; Aragon-Ching, Jeanny B. (2017-09-22)
    Enzalutamide, previously known as MDV300, is an oral, second-generation androgen receptor (AR) signaling inhibitor or antagonist that was approved by the Food and Drug Administration in 2012 for the treatment of metastatic ...
  • New pharmacotherapies in the treatment of advanced prostate cancer 
    El-Amm, Joelle; El-Ayass, Walid; Jain, Maneesh; Aragon-Ching, Jeanny B. (2017-09-25)
    Recent drug approvals in the field of prostate cancer therapy have brought about a change in the treatment landscape of locally advanced and metastatic castration-resistant prostate cancer. While this improvement offers ...
  • Primary diffuse large B-cell lymphoma of the ureter in a patient with HIV 
    El-Amm, Joelle; Ruth, Kenneth; Sotelo, Tiffany; Aragon-Ching, Jeanny B. (2017-09-22)
  • Radium-223 for the treatment of castration-resistant prostate cancer 
    El-Amm, Joelle; Aragon-Ching, Jeanny B. (2017-09-25)
    The vast majority of patients with metastatic castration-resistant prostate cancer (mCRPC) develop bone metastases. Bone metastases are a source of significant morbidity and affect quality of life in these patients. Several ...
  • Targeting bone metastases in metastatic castration-resistant prostate cancer 
    El-Amm, Joelle; Aragon-Ching, Jeanny B. (2017-09-22)
    Skeletal involvement in metastatic castrate-resistant prostate cancer (mCRPC) is common and results in significant morbidity and mortality. The interaction of prostate cancer with the bone microenvironment contributes to ...
  • Use of denosumab for renal cell carcinoma-associated malignant hypercalcemia 
    El-Amm, Joelle; Freeman, Ashley; Aragon-Ching, Jeanny B. (2017-09-25)
  • Vosaroxin for acute myeloid leukemia 
    El-Amm, Joelle; Tabbara, Imad A. (2017-09-25)
    The treatment of acute myeloid leukemia (AML) in adults has not significantly changed in the past five decades. Despite the availability of effective induction chemotherapy, most patients eventually relapse. Relapsed ...

Search LAUR


Advanced Search

Browse

My Account